FOLD Stock Recent News

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?

Amicus Therapeutics, Inc., with two approved rare disease therapies, shows strong revenue growth and market potential despite a 30% stock decline since 2021. Galafold and Pombiliti+Opfolda are driving revenue, with significant market share and potential label expansions, targeting $1bn revenue by 2028. The company has a solid financial position, minimal near-term competition, and a favorable patent settlement with Teva, ensuring market exclusivity until 2037.

Hampton Dellinger v. Scott Bessent, Secretary of the Treasury, et al. Hampton Dellinger v. Scott Bessent, Secretary of the Treasury, et al.

Texas Top Cop Shop, Inc., et al. v. Pamela Bondi, Attorney General of the United States, et al. Texas Top Cop Shop, Inc., et al. v. Pamela Bondi, Attorney General of the United States, et al.

PRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in March.

Amicus' fourth-quarter 2024 earnings miss estimates while revenues beat the same.

Although the revenue and EPS for Amicus Therapeutics (FOLD) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating Amicus Therapeutics, Inc. (NASDAQ: FOLD) (“Amicus”) on behalf of the company's shareholders. Click here for additional information: https://kaskelalaw.com/case/amicus-therapeutics/ Since December 2023, shares of Amicus' common stock have declined in value from a trading price of $14.50 per share to a current trading price of approximately $11.00 per share, a decline of nearly 25% in value. The investigation seeks.

Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q4 2024 Earnings Conference Call February 19, 2025 8:30 AM ET Company Participants Andrew Faughnan - Vice President, Investor Relations Bradley Campbell - President and Chief Executive Officer Sebastien Martel - Chief Business Officer Jeffrey Castelli - Chief Development Officer Simon Harford - Chief Financial Officer Conference Call Participants Tazeen Ahmad - Bank of America Securities Ellie Merle - UBS Dennis Ding - Jefferies Joe Schwartz - Leerink Partners Kristen Kluska - Cantor Fitzgerald Malcolm Kuno - JPMorgan Salveen Richter - Goldman Sachs Gil Blum - Needham & Company Jeff Hung - Morgan Stanley Joshua Fleishman - TD Cowen Operator Good morning, ladies and gentlemen. And welcome to the Amicus Therapeutics Full Year 2024 Financial Results Conference Call and Webcast.

Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to loss of $0.11 per share a year ago.